205 related articles for article (PubMed ID: 4319923)
1. Drug-induced changes in brain dopamine and their relation to parkinsonism.
Vogt M
Sci Basis Med Annu Rev; 1970; ():276-91. PubMed ID: 4319923
[No Abstract] [Full Text] [Related]
2. [The role of dopamine in the physiology and pathology of the basal ganglia].
Arushanian EB
Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(4):595-603. PubMed ID: 4341763
[No Abstract] [Full Text] [Related]
3. Dopamine and extrapyramidal motor function and dysfunction.
Hornykiewicz O
Res Publ Assoc Res Nerv Ment Dis; 1972; 50():390-415. PubMed ID: 4561070
[No Abstract] [Full Text] [Related]
4. The metabolism of brain dopamine in human parkinsonism.
Hornykiewicz O
Riv Patol Nerv Ment; 1970 Oct; 91(5):281-6. PubMed ID: 5525774
[No Abstract] [Full Text] [Related]
5. Parkinson's disease: from brain homogenate to treatment.
Hornykiewicz O
Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
[No Abstract] [Full Text] [Related]
6. [Dopaminergic conception of Parkinsonism and its treatment with L-DOPA].
Levin SL
Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(9):1418-26. PubMed ID: 4349303
[No Abstract] [Full Text] [Related]
7. Physiologic, biochemical, and pathological backgrounds of levodopa and possibilities for the future.
Hornykiewicz OD
Neurology; 1970 Dec; 20(12):1-5. PubMed ID: 5531292
[No Abstract] [Full Text] [Related]
8. [l-dopa treatment of Parkinson's syndrome and mechanism of action of neuroleptics].
Degkwitz R
Med Klin; 1969 Aug; 64(33):1451-6. PubMed ID: 4896563
[No Abstract] [Full Text] [Related]
9. Synaptic plasticity, dopamine and Parkinson's disease: one step ahead.
Calabresi P; Mercuri NB; Di Filippo M
Brain; 2009 Feb; 132(Pt 2):285-7. PubMed ID: 19168452
[No Abstract] [Full Text] [Related]
10. Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor.
Rinne UK; Sonninen V
Arch Neurol; 1973 Feb; 28(2):107-10. PubMed ID: 4683147
[No Abstract] [Full Text] [Related]
11. Biochemical aspects of experimentally induced parkinsonism.
Goldstein M; Anagnoste B; Battista AF; Nakatani S; Ogawa M
Res Publ Assoc Res Nerv Ment Dis; 1972; 50():434-47. PubMed ID: 4403657
[No Abstract] [Full Text] [Related]
12. Biochemical and pharmacological aspects of Parkinsonism.
Carlsson A
Acta Neurol Scand Suppl; 1972; 51():11-42. PubMed ID: 4351191
[No Abstract] [Full Text] [Related]
13. Dopaminergic nervous transmission in Parkinson's disease.
Rinne UK; Sonninen V; Riekkinen P; Laaksonen H
Med Biol; 1974 Jun; 52(3):208-17. PubMed ID: 4371255
[No Abstract] [Full Text] [Related]
14. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
Orzi F; Fornai F; Blandini F
Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
[No Abstract] [Full Text] [Related]
15. [Dopamine and parkinsonism].
Siegfried J
Schweiz Med Wochenschr; 1968 Mar; 98(11):429-31. PubMed ID: 5700507
[No Abstract] [Full Text] [Related]
16. L-dopa in Parkinsonism. A possible mechanism of action.
Ng LK; Chase TN; Colburn RW; Kopin IJ
Neurology; 1972 Jul; 22(7):688-96. PubMed ID: 4673250
[No Abstract] [Full Text] [Related]
17. Cerebral catecholamines after levodopa therapy.
Greer M; Collins GH; Anton AH
Arch Neurol; 1971 Nov; 25(5):461-7. PubMed ID: 5110888
[No Abstract] [Full Text] [Related]
18. Recent views on tremors and their treatment.
Poirier LJ
Mod Trends Neurol; 1970; 5(0):80-95. PubMed ID: 4369120
[No Abstract] [Full Text] [Related]
19. [Drug-induced Parkinson's syndrome].
Degkwitz R
Dtsch Med Wochenschr; 1972 Jun; 97(22):882. PubMed ID: 5032182
[No Abstract] [Full Text] [Related]
20. Drugs affecting monoamines in the basal ganglia.
Bartholini G; Pletscher A
Adv Biochem Psychopharmacol; 1972; 6():135-48. PubMed ID: 4560163
[No Abstract] [Full Text] [Related]
[Next] [New Search]
